PPMD was joined by Edgewise Therapeutics for a community webinar on May 3, 2023 to discuss the company’s novel approach designed to protect muscle in individuals living with Becker muscular dystrophy.

The webinar highlighted EDG-5506, an investigational compound, in the form of a daily oral pill, that could be used alone or in combination with other therapies, regardless of mutation. Our presenters also discussed results from the ongoing open-label ARCH study in adults with Becker muscular dystrophy and the currently enrolling, CANYON phase 2 trial for adolescents and adults living with Becker.